Alvotech and teva announce u.s. fda approval of selarsdi™ (ustekinumab-aekn), biosimilar to stelara® (ustekinumab)

Reykjavik, iceland and parsippany, n.j., april 16, 2024 (globe newswire) -- alvotech (nasdaq: alvo) and teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced that the u.s. food and drug administration (fda) has approved selarsdi (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. under the strategic partnership between teva and alvotech, teva is responsible for the exclusive commercialization of selarsdi in the united states.
ALVO Ratings Summary
ALVO Quant Ranking